Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injury; A Randomized Double-Blind Placebo-Controlled Clinical Trial.

Related Articles

Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injury; A Randomized Double-Blind Placebo-Controlled Clinical Trial.

World Neurosurg. 2017 Feb 06;:

Authors: Khalili H, Derakhshan N, Niakan A, Ghaffarpasand F, Salehi M, Eshraghian H, Shakibafard A, Zahabi B

Abstract
OBJECTIVE: The aim of the current study was to investigate the effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury (TBI).
METHODS: This was randomized clinical trial being conducted during a 16-month period from May 2015 and August 2016 in a level I trauma center in Southern Iran. We included 66 patients with moderate (GCS: 9-13) to severe (GCS: 5-8) TBI who had brain contusions of less than 30cc volume. We excluded those who required surgical intervention. Patients were randomly assigned to receive daily 10 mg oral Glibenclamide for 10 days (n=29) or placebo in the same dosage (n=23). The brain contusion volumetry was performed on days 0, 3 and 7 utilizing spiral thin-cut brain CT-Scan (1-mm thickness). The outcome measured included modified Rankin scale (MRS), Glasgow Outcome Scale (GOS) and Disability rating Scale (DRS) which were all evaluated 3 months post-injury.
RESULTS: There was no significant difference between two study group regarding the baseline, 3(rd) day and 7(th) day of the contusion volume. However, those receiving glibenclamide had significantly lower expansion ratio from first to second volumetry (p<0.001). In the same way, the first to third expansion ratio was significantly lower in glibenclamide group compared to placebo (p=0.003). There was no significant difference between the two study groups regarding the functional outcome measured by GOS, MRS and DRS.
CONCLUSIONS: Oral glibenclamide is associated with decreased contusion expansion rate in patients with moderate and severe TBI sustaining cerebral contusions.

PMID: 28185976 [PubMed - as supplied by publisher]

http://ift.tt/2kyMpPm